麥瀾德(688273.SH):目前生殖康復相關產品在市面上具有先發優勢
格隆匯3月6日丨麥瀾德(688273.SH)於2023年2月27日接受機構調研時表示,在盆底康復板塊,①公司發明了一次性篩查方法及一次性陰道電極,解決了耗材成本高的痛點,滿足了大規模人羣篩查的需求;②發明智能化算法,針對不同病症,不同人羣,個性化有效應對的方案、可打分易讀的報吿,解決了原先市面上設備操作複雜,學習曲線和成本高的痛點,滿足了簡化操作,降低學習成本,降低醫患溝通成本,提高依從性的需求;③建立分級診療系統,技術層面支持醫院和家用聯網,數據互通,解決了診療數據割裂,滿足了隨時隨地切換場景、簡單有效地做盆底康復的需求。
在生殖康復板塊,公司完成了兩個能量技術平台的整合,將聚焦超聲和生物電刺激融合,進行產品結構上的創新,發明了宮頸電極,目前生殖康復相關產品在市面上具有先發優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.